PURPOSE: The primary purpose of surveillance of patients with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local therapy (eg, chemoradiotherapy followed by surgery or trimodality therapy [TMT]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality caused by locoregional failure (LRF). However, the benefits of surveillance are not well understood. We report on LRFs and salvage strategies in a large cohort. PATIENTS AND METHODS: Between 2000 and 2010, 518 patients with EAC who completed TMT were analyzed for the frequency of LRF over time and salvage therapy outcomes. Standard statistical techniques were used. RESULTS: For 518 patients, the median follow-up time was 29.3 months (range, 1 to 149 months). Distant metastases (with or without LRF) occurred in 188 patients (36%), and LRF only occurred in 27 patients (5%). Eleven of 27 patients had lumen-only LRF. Most LRFs (89%) occurred within 36 months of surgery. Twelve patients had salvage chemoradiotherapy, but only five survived more than 2 years. Four patients needed salvage surgery, and three who survived more than 2 years developed distant metastases. The median overall survival of 27 patients with LRF was 17 months, and 10 patients (37%) survived more than 2 years. Thus, only 2% of all 518 patients benefited from surveillance/salvage strategies. CONCLUSION: Our surveillance strategy, which is representative of many others currently being used, raises doubts about its effectiveness and benefits (along with concerns regarding types and times of studies and costs implications) to patients with EAC who have LRF only after TMT. Fortunately, LRFs are rare after TMT, but the salvage strategies are not highly beneficial. Our data can help develop an evidence-based surveillance strategy.
PURPOSE: The primary purpose of surveillance of patients with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local therapy (eg, chemoradiotherapy followed by surgery or trimodality therapy [TMT]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality caused by locoregional failure (LRF). However, the benefits of surveillance are not well understood. We report on LRFs and salvage strategies in a large cohort. PATIENTS AND METHODS: Between 2000 and 2010, 518 patients with EAC who completed TMT were analyzed for the frequency of LRF over time and salvage therapy outcomes. Standard statistical techniques were used. RESULTS: For 518 patients, the median follow-up time was 29.3 months (range, 1 to 149 months). Distant metastases (with or without LRF) occurred in 188 patients (36%), and LRF only occurred in 27 patients (5%). Eleven of 27 patients had lumen-only LRF. Most LRFs (89%) occurred within 36 months of surgery. Twelve patients had salvage chemoradiotherapy, but only five survived more than 2 years. Four patients needed salvage surgery, and three who survived more than 2 years developed distant metastases. The median overall survival of 27 patients with LRF was 17 months, and 10 patients (37%) survived more than 2 years. Thus, only 2% of all 518 patients benefited from surveillance/salvage strategies. CONCLUSION: Our surveillance strategy, which is representative of many others currently being used, raises doubts about its effectiveness and benefits (along with concerns regarding types and times of studies and costs implications) to patients with EAC who have LRF only after TMT. Fortunately, LRFs are rare after TMT, but the salvage strategies are not highly beneficial. Our data can help develop an evidence-based surveillance strategy.
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: Jaffer A Ajani; James S Barthel; David J Bentrem; Thomas A D'Amico; Prajnan Das; Crystal S Denlinger; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Mary F Mulcahy; Mark B Orringer; Raymond U Osarogiagbon; James A Posey; Aaron R Sasson; Walter J Scott; Stephen Shibata; Vivian E M Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright Journal: J Natl Compr Canc Netw Date: 2011-08-01 Impact factor: 11.908
Authors: Jenifer L Marks; Wayne Hofstetter; Arlene M Correa; Reza J Mehran; David Rice; Jack Roth; Garrett Walsh; Ara Vaporciyan; Jeremy Erasmus; Joe Chang; Dipen Maru; Jeffrey H Lee; Jared Lee; Jaffer A Ajani; Stephen G Swisher Journal: Ann Thorac Surg Date: 2012-08-24 Impact factor: 4.330
Authors: Matthew Koshy; Bruce D Greenwald; Petr Hausner; Mark J Krasna; Naomi Horiba; Richard J Battafarano; Whitney Burrows; Mohan Suntharalingam Journal: Am J Clin Oncol Date: 2011-06 Impact factor: 2.339
Authors: J A Ajani; A M Correa; W L Hofstetter; D C Rice; M A Blum; A Suzuki; T Taketa; J Welsh; S H Lin; J H Lee; M S Bhutani; W A Ross; D M Maru; H A Macapinlac; J Erasmus; R Komaki; R J Mehran; A A Vaporciyan; S G Swisher Journal: Ann Oncol Date: 2012-07-24 Impact factor: 32.976
Authors: Elena Elimova; Xuemei Wang; Wei Qiao; Kazuki Sudo; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Venkatram Planjery; Nikolaos Charalampakis; Jeffrey H Lee; Brian R Weston; Manoop S Bhutani; Ritsuko Komaki; David C Rice; Stephen G Swisher; Mariela A Blum; Jane E Rogers; Heath D Skinner; Dipen M Maru; Wayne L Hofstetter; Jaffer A Ajani Journal: Oncology Date: 2018-04-27 Impact factor: 2.935
Authors: Fatemeh G Amlashi; Xuemei Wang; Raquel E Davila; Dipen M Maru; Manoop S Bhutani; Jeffrey H Lee; Brian R Weston; Dilsa Mizrak Kaya; Maria Vassilakopoulou; Kazuto Harada; Mariela A Blum Murphy; David C Rice; Wayne L Hofstetter; Marta Davila; Quynh-Nhu Nguyen; Jaffer A Ajani Journal: Oncology Date: 2018-05-29 Impact factor: 2.935
Authors: Hironori Shiozaki; Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Elena Elimova; Wayne L Hofstetter; Heath D Skinner; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela A Blum; Dipen M Maru; Jaffer A Ajani Journal: Oncology Date: 2014-06-07 Impact factor: 2.935
Authors: Mian Xi; Zhongxing Liao; Wayne L Hofstetter; Ritsuko Komaki; Linus Ho; Steven H Lin Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Hironori Shiozaki; Rebecca Slack; Kazuki Sudo; Elena Elimova; Roopma Wadhwa; Hsian-Chun Chen; Heath D Skinner; Ritsuko Komaki; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela A Blum; Jane E Rogers; Dipen M Maru; Wayne L Hofstetter; Jaffer A Ajani Journal: Oncology Date: 2015-02-28 Impact factor: 2.935
Authors: Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Hironori Shiozaki; Elena Elimova; Takashi Taketa; Mariela A Blum; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William A Ross; Ritsuko Komaki; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Dipen M Maru; Heath D Skinner; Jaffer A Ajani Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: J Y Liu; F Li; L P Wang; X F Chen; D Wang; L Cao; Y Ping; S Zhao; B Li; S H Thorne; B Zhang; P Kalinski; Y Zhang Journal: Br J Cancer Date: 2015-08-18 Impact factor: 7.640